Carlyle Group will purchase a 20% stake in Indian billionaire Ajay Piramal’s pharmaceutical business, according to an exchange filing.
The private equity fund will pay $490 million for the holding, valuing the business at an enterprise value of $2.7 billion. In addition to helping expand capacity of the pharmaceutical operations, the Piramal group will use the money to repay some of parent Piramal Enterprises Ltd.’s debt, the filing said.
“This infusion of funds will further strengthen our balance sheet and provide us with a war chest for the next phase of our strategy,” Ajay Piramal, chairman of Piramal Enterprises, said in the filing.
In May, Carlyle agreed to buy up to 74% of SeQuent Scientific, the largest pure-play animal healthcare company in India.
Source: Bloomberg
Can’t stop reading? Read more
Thoma Bravo’s SailPoint targets $11.5bn valuation in US IPO
Cybersecurity firm SailPoint is preparing to go public again in the US, targeting a valuation of...
Balbec Capital closes sixth credit fund at $1.7bn, marking record fundraise
Balbec Capital closed its latest credit fund, Insolve Global Credit Fund VI, securing over $1.7bn...
The saga continues: Brookfield enters $1.9bn bidding war for Insignia Financial
Brookfield Asset Management joined Bain Capital and CC Capital in the race to acquire Insignia...